BR9713130A - Promoter region of bmp-4 and its fragments, vector comprising a promoter region of bmp-4 or its fragments, host cell, process for the identification of therapeutic agents for the prevention and / or treatment of osteoporosis, and use of ici 164384. - Google Patents
Promoter region of bmp-4 and its fragments, vector comprising a promoter region of bmp-4 or its fragments, host cell, process for the identification of therapeutic agents for the prevention and / or treatment of osteoporosis, and use of ici 164384.Info
- Publication number
- BR9713130A BR9713130A BR9713130-0A BR9713130A BR9713130A BR 9713130 A BR9713130 A BR 9713130A BR 9713130 A BR9713130 A BR 9713130A BR 9713130 A BR9713130 A BR 9713130A
- Authority
- BR
- Brazil
- Prior art keywords
- bmp
- fragments
- promoter region
- therapeutic agents
- vector
- Prior art date
Links
- 108700039691 Genetic Promoter Regions Proteins 0.000 title abstract 6
- 239000012634 fragment Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 239000013598 vector Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 101150067309 bmp4 gene Proteins 0.000 title 2
- BVVFOLSZMQVDKV-KXQIQQEYSA-N ICI-164384 Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](CCCCCCCCCCC(=O)N(C)CCCC)CC3=CC(O)=CC=C3[C@H]21 BVVFOLSZMQVDKV-KXQIQQEYSA-N 0.000 title 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 4
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract 4
- 239000013604 expression vector Substances 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108700008625 Reporter Genes Proteins 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 229940124606 potential therapeutic agent Drugs 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
"REGIãO PROMOTORA DE BMP-4 E SEUS FRAGMENTOS VETOR COMPREENDENDO UMA REGIãO PROMOTORA DE BMP-4 OU SEUS FRAGMENTOS, CéLULA HOSPEDEIRA, PROCESSO PARA A IDENTIFICAçãO DE AGENTES TERAPêUTICOS PARA A PREVENçãO E/OU TRATAMENTO DA OSTEOPOROSE, E, USO DE ICI 164384". A presente invenção diz respeito a uma região promotora da proteína morfogenética dos ossos (BMP-4) de seres humanos, e a seus fragmentos, a um vetor compreendendo dita região promotora, e células hospedeiras compreendendo ditas regiões promotoras ou vetores. A invenção ainda diz respeito a um processo para a identificação de agentes terapêuticos para uso na prevenção e/ou tratamento da osteoporose, em que dito processo compreende as etapas de: a) introduzir em uma célula um primeiro vetor de expressão compreendendo uma região promotora BMP-4 ou seus fragmentos operavelmente ligados a um gene repórter, e um segundo vetor de expressão compreendendo DNA codificando o receptor de estrogênio; b) fazer o contato da dita célula com agentes terapêuticos potenciais; c) monitorar a expressão da proteína codificada pelo gene reportado."BMP-4 PROMOTING REGION AND ITS FRAGMENTS VECTOR UNDERSTANDING A BMP-4 PROMOTING REGION OR ITS FRAGMENTS, HOST CELL, PROCESS FOR THE IDENTIFICATION OF THERAPEUTIC AGENTS FOR THE PREVENTION AND / OR TREATMENT OF OSTE4, 164 . The present invention relates to a promoter region of human bone morphogenetic protein (BMP-4), and fragments thereof, to a vector comprising said promoter region, and host cells comprising said promoter regions or vectors. The invention also concerns a process for the identification of therapeutic agents for use in the prevention and / or treatment of osteoporosis, in which said process comprises the steps of: a) introducing into a cell a first expression vector comprising a BMP promoter region -4 or fragments thereof operably linked to a reporter gene, and a second expression vector comprising DNA encoding the estrogen receptor; b) making contact of said cell with potential therapeutic agents; c) monitor the expression of the protein encoded by the reported gene.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96203283 | 1996-11-22 | ||
| PCT/EP1997/006668 WO1998023740A1 (en) | 1996-11-22 | 1997-11-20 | Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9713130A true BR9713130A (en) | 2000-02-08 |
Family
ID=8224612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9713130-0A BR9713130A (en) | 1996-11-22 | 1997-11-20 | Promoter region of bmp-4 and its fragments, vector comprising a promoter region of bmp-4 or its fragments, host cell, process for the identification of therapeutic agents for the prevention and / or treatment of osteoporosis, and use of ici 164384. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6159696A (en) |
| EP (1) | EP0937145A1 (en) |
| JP (1) | JP2001509010A (en) |
| AU (1) | AU5558498A (en) |
| BR (1) | BR9713130A (en) |
| CA (1) | CA2272345A1 (en) |
| WO (1) | WO1998023740A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11313675A (en) * | 1998-04-30 | 1999-11-16 | Hoechst Marion Roussel Kk | Human BMP-7 promoter and method for searching for bone-related substances using the same |
| JPH11313674A (en) * | 1998-04-30 | 1999-11-16 | Hoechst Marion Roussel Kk | Human BMP-4 promoter and method for searching for bone-related substances using the same |
| JP2000004882A (en) * | 1998-06-18 | 2000-01-11 | Hoechst Marion Roussel Kk | Human MP52 gene promoter and method for searching for useful substances using the same |
| US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
| US7427677B2 (en) * | 2003-07-01 | 2008-09-23 | Academia Sinica | Expression of zebrafish bone morphogenetic protein 4 |
| CN100410384C (en) * | 2004-12-08 | 2008-08-13 | 上海第二医科大学附属第九人民医院 | Retroviral Vector of Bone Morphogenetic Protein 4 Gene and Its Application |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83003A (en) * | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| IL109990A (en) * | 1993-06-21 | 1999-06-20 | Lilly Co Eli | Materials and methods for screening anti-osteoporosis agents |
| CA2191583C (en) * | 1994-06-07 | 2007-03-27 | Engin Ozkaynak | Methods and compositions for modulating morphogenic protein expression |
| US6083690A (en) * | 1995-06-02 | 2000-07-04 | Osteoscreen, Inc. | Methods and compositions for identifying osteogenic agents |
| DE69605600T2 (en) * | 1995-06-06 | 2000-05-31 | Eli Lilly And Co., Indianapolis | Anti-estrogen combinations reduce bone loss |
-
1997
- 1997-11-20 EP EP97952013A patent/EP0937145A1/en not_active Withdrawn
- 1997-11-20 BR BR9713130-0A patent/BR9713130A/en not_active Application Discontinuation
- 1997-11-20 CA CA002272345A patent/CA2272345A1/en not_active Abandoned
- 1997-11-20 WO PCT/EP1997/006668 patent/WO1998023740A1/en not_active Ceased
- 1997-11-20 JP JP52429798A patent/JP2001509010A/en active Pending
- 1997-11-20 AU AU55584/98A patent/AU5558498A/en not_active Abandoned
- 1997-11-20 US US09/308,406 patent/US6159696A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998023740A1 (en) | 1998-06-04 |
| JP2001509010A (en) | 2001-07-10 |
| EP0937145A1 (en) | 1999-08-25 |
| AU5558498A (en) | 1998-06-22 |
| US6159696A (en) | 2000-12-12 |
| CA2272345A1 (en) | 1998-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9609006A (en) | Peptide, pharmaceutical composition, and process for treating the patient. | |
| BR9712348A (en) | isolated polynucleotide molecule, expression vector, cultured cell into which an expression vector was introduced, process to produce an isolated fgf homologous polypeptide, isolated fgf homologous polypeptide, pharmaceutical composition, antibody, processes to stimulate ex vivo myocyte progenitor cells, and, paralyzing an agent or drug selectively for heart tissue. | |
| BR9407035A (en) | Fragment of keratinocyte growth factor conjugated therapeutic composition DNA molecule expression vector host cell process to produce fragment of keratinocyte growth factor process for wound healing and process of treatment of hyperproliferative disease of the epidermis | |
| BR9814984A (en) | Processes to treat physical conditions resulting from postmenopausal estrogen decline in a postmenopausal patient and to reduce the risk of osteoporotic bone fractures in a patient, and, set for use by a consumer tormented with, or susceptible to, resulting physical conditions of postmenopausal estrogen decline | |
| BR9713755A (en) | Protein, fusion protein, nucleic acid sequence, vector, prokaryotic or eukaryotic host cell, process for producing a protein, pharmaceutical composition, and process for treating a disorder. | |
| PT698094E (en) | BMP-11 COMPOSITIONS | |
| EP0701563A4 (en) | GENE TRANSFER FOR THE TREATMENT OF CONNECTIVE TISSUES IN A HOST MAMMAL | |
| BR0107613A (en) | Blockade of axon growth mediated by nogo receptor | |
| BR9914643A (en) | Adeno-associated vectors for dofactor viii expression by target cells | |
| MX9700270A (en) | Nucleic acid containing composition, preparation and uses of same. | |
| BR9508467A (en) | Somatostatin receptor binding peptide matter composition pharmaceutical composition and process for performing radiosotope-guided surgery or a radiodiagnostic or radiotherapeutic procedure and for alleviating a somatostetin-related disease in an animal | |
| BR9803960A (en) | D-sorbitol dehydrogenase gene. | |
| BR9909958A (en) | Pharmaceutical formulation, respective preparation and use process and method of treatment or prevention of bone disorders | |
| ATE191922T1 (en) | DETERMINATION OF THE INTERACTION SITE BETWEEN P21-WAF AND PCNA AND THEIR THERAPEUTIC USES | |
| BR9713130A (en) | Promoter region of bmp-4 and its fragments, vector comprising a promoter region of bmp-4 or its fragments, host cell, process for the identification of therapeutic agents for the prevention and / or treatment of osteoporosis, and use of ici 164384. | |
| BR0213965A (en) | Composition and method for altering lean and bony body mass properties in an individual | |
| PT1028744E (en) | NEURONAL UTILIZATIONS OF BMP-11 | |
| BR9912594A (en) | Graft versus host disease inhibition | |
| EP1609856A3 (en) | Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof | |
| BR9910585A (en) | Human bmp-7 promoter and method for exploring bone-related substance using the same | |
| Pellegrini Jr et al. | Pathobiology of articular cartilage in trapeziometacarpal osteoarthritis. I. Regional biochemical analysis | |
| BR9910594A (en) | Herpes simplex virus, use of a herpessimplex virus, pharmaceutical composition and processes to study the function of a heterologous gene in a mammalian cell, to produce a herpes simplex virus and to treat a disorder or injury of a mammalian nervous system | |
| NZ504327A (en) | Gene expressed in hypothalamus of obese animals and pharmaceutical use | |
| BR9801985A (en) | Creamy composition applied in the therapy of peyronie's disease. | |
| BR9813919A (en) | Isolated nucleic acid fragment, chimeric gene, transformed host cell, sclb ^ r ^ polypeptide, method for altering the expression level of a sclb ^ r ^ protein, method for obtaining a nucleic acid fragment and product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| FA8 | Dismissal: dismissal - article 36, par. 1 of industrial property law |